<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05091424</url>
  </required_header>
  <id_info>
    <org_study_id>BO43243</org_study_id>
    <nct_id>NCT05091424</nct_id>
  </id_info>
  <brief_title>A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia</brief_title>
  <official_title>A Phase IB Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the safety, tolerability, pharmaokinetics, and preliminary efficacy of&#xD;
      mosunetuzumab in participants with relapsed or refractory (R/R) chronic lymphocytic leukemia&#xD;
      (CLL).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2021</start_date>
  <completion_date type="Anticipated">October 10, 2025</completion_date>
  <primary_completion_date type="Anticipated">April 18, 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Dose-Limiting Toxicities (DLTs)</measure>
    <time_frame>Up to approximately 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Up to 8-12 weeks after the last dose of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimal Residual Disease (MRD) Response Rate</measure>
    <time_frame>Up to 8-12 weeks after the last dose of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>From the first study treatment to the first occurrence of disease progression or death from any cause, whichever occurs first (up to approximately 12 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>From the first dose of study drug to death from any cause (up to approximately 12 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-Free Survival (EFS)</measure>
    <time_frame>Between the date of the first study treatment to the date of disease progression/relapse, death, or start of new anti-leukemic therapy (up to approximately 12 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Response (CR) Rate</measure>
    <time_frame>Up to 8-12 weeks after the last dose of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>From the first occurrence of a documented objective response to disease progression by iwCLL 2018 criteria or death from any cause (up to approximately 12 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Adverse Events (AEs)</measure>
    <time_frame>Up to approximately 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Serum Concentration (Cmax) of Mosunetuzumab SC</measure>
    <time_frame>Up to approximately 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum Serum Concentration (Cmin) of Mosunetuzumab SC</measure>
    <time_frame>Up to approximately 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum Concentration (Tmax) of Mosunetuzumab SC</measure>
    <time_frame>Up to approximately 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <arm_group>
    <arm_group_label>R/R CLL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive weekly step-up dosing of mosunetuzumab until the target dose is reached, after which mosunetuzumab will be administered once every 21 days for up to 17 cycles (cycle = 21 days) or until objective disease progression or unacceptable toxicity, whichever occurs first.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mosunetuzumab</intervention_name>
    <description>Participants will receive subcutaneous (SC) mosunetuzumab for up to 17 cycles (cycle = 21 days).</description>
    <arm_group_label>R/R CLL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tocilizumab</intervention_name>
    <description>Participants will receive intravenous (IV) tocilizumab as needed for cytokine release syndrome (CRS) events.</description>
    <arm_group_label>R/R CLL</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have a diagnosis of CLL requiring treatment according to the International Workshop on&#xD;
             CLL (iwCLL) criteria (Hallek et al 2018)&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance score (PS) of â‰¤ 2&#xD;
&#xD;
          -  Adequate bone marrow (BM) function independent of growth factor or transfusion&#xD;
             support, within 2 weeks of screening, at screening as defined by the protocol unless&#xD;
             cytopenia is clearly due to marrow involvement of CLL&#xD;
&#xD;
          -  Adequate liver function unless directly attributable to the participant's CLL&#xD;
&#xD;
          -  Life expectancy &gt; 6 months&#xD;
&#xD;
          -  For women of childbearing potential: agreement to remain abstinent (refrain from&#xD;
             heterosexual intercourse) or use contraceptive methods that result in a failure rate&#xD;
             of &lt; 1% per year, and agreement to refrain from donating eggs during the treatment&#xD;
             period and for at least 3 months after the last dose of mosunetuzumab and 3 months&#xD;
             after the last dose of tocilizumab (if applicable)&#xD;
&#xD;
          -  For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use&#xD;
             a condom, and agreement to refrain from donating sperm as defined by the protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or breastfeeding, or intending to become pregnant during the study or within&#xD;
             3 months after the final dose of mosunetuzumab and tocilizumab (if applicable)&#xD;
&#xD;
          -  Participants who have received any of the following treatments prior to study entry:&#xD;
             treatment with mosunetuzumab or other CD20/CD3-directed bispecific antibodies;&#xD;
             allogenic stem cell transplant&#xD;
&#xD;
          -  Participants who have received any of the following treatments, whether&#xD;
             investigational or approved, within the respective time periods prior to initiation of&#xD;
             study treatment: radiotherapy within 2 weeks prior to the first dose of study&#xD;
             treatment; autologous stem cell transplant within 100 days prior to first study&#xD;
             treatment; CAR T-cell therapy within 30 days before first study treatment; use of&#xD;
             monoclonal antibodies or antibody-drug conjugates within 4 weeks prior to first study&#xD;
             treatment; systemic immunosuppressive medications (including but not limited to&#xD;
             cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis&#xD;
             factor agents) within 2 weeks prior to the first dose of study treatment; any other&#xD;
             anti-cancer therapy, whether investigational or approved, including but not limited to&#xD;
             chemotherapy within 4 weeks or 5 half-lives of the drug, whichever is shorter, prior&#xD;
             to initiation of study treatment; other prior cancer immunotherapy not explicitly&#xD;
             defined by the protocol is to be discussed with the medical monitor to determine&#xD;
             eligibility&#xD;
&#xD;
          -  Received a live, attenuated vaccine within 4 weeks before the first dose of study&#xD;
             treatment, or in whom it is anticipated that such a vaccine will be required during&#xD;
             the study period or within 5 months after the final dose of study treatment&#xD;
&#xD;
          -  Transformation of CLL to aggressive non-Hodgkin's lymphoma (NHL)&#xD;
&#xD;
          -  History of severe allergic or anaphylactic reactions to humanized or murine monoclonal&#xD;
             antibody therapy (or recombinant antibody-related fusion proteins)&#xD;
&#xD;
          -  Contraindication to tocilizumab&#xD;
&#xD;
          -  History of prior malignancy except for conditions defined by the protocol&#xD;
&#xD;
          -  Participants with infections requiring intravenous (IV) treatment with antibiotics or&#xD;
             hospitalization within the last 4 weeks prior to enrollment or known active bacterial,&#xD;
             viral (including SARS-CoV-2), fungal, mycobacterial, parasitic, or other infection&#xD;
             (excluding fungal infections of nail beds) at study enrollment&#xD;
&#xD;
          -  Evidence of any significant concomitant disease that could affect compliance with the&#xD;
             protocol or interpretation of results&#xD;
&#xD;
          -  Recent major surgery within 4 weeks prior to first study treatment administration,&#xD;
             with the exception of protocol-mandated procedures (e.g., tumor biopsies and bone&#xD;
             marrow biopsies)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reference Study ID Number: BO43243 https://forpatients.roche.com/</last_name>
    <phone>888-662-6728</phone>
    <email>global-roche-genentech-trials@gene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau; Servicio de Hematologia</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <removed_countries>
    <country>Australia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 12, 2021</study_first_submitted>
  <study_first_submitted_qc>October 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 25, 2021</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

